David Hanna is a senior counsel in the Life Sciences Group in the Litigation Department, where he focuses on biologic drug patent and Hatch-Waxman patent litigation. David’s biologics drug patent litigation experience includes litigating matters relating to Stelara® (ustekinumab), Avastin® (bevacizumab), and Herceptin® (trastuzumab).
David has represented both patentees and generic filers in Hatch-Waxman litigation. He has litigated matters relating to Imbruvica® (ibrutinib), Xarelto® (rivaroxaban), Suboxone® (buprenorphine naloxone), Pradaxa® (dabigatran etexilate), Ultiva® (remifentanil hydrochloride), Daytrana® (methylphenidate), Dymista® (azelastine HCl/fluticasone propionate), Epaned® (enalapril maleate), and Brisdelle® (paroxetine).
David has also represented a major pharmaceutical company in product liability matters relating to Viread®, Truvada®, Atripla®, and other antiviral medications containing tenofovir disoproxil fumarate (“TDF”).
In the top law firm directory The Legal 500 US, a client recommended David, noting his client service for being “super responsive and very detail oriented.”
David additionally advocates for LGBTQ+ equality, including filing administrative complaints under the Federal Tort Claims Act, preparing and filing asylum applications and supporting documentation, and petitioning for legal name changes.
Lead Article Editor, Minnesota Journal of Law, Science & Technology
Chemistry
Chemistry, summa cum laude
Member at Large, SCALACS Executive Committee
Board Member, Echo Theater Company
LGBTQ+ Lawyers Association of Los Angeles
American Chemical Society
Best Lawyers in America: Ones to Watch 2021-2024
The Legal 500 United States: Healthcare: Life Sciences 2020
Southern California Super Lawyers: Rising Star 2020-2024
Federal Circuit Bar Association Global Fellow 2022-2023
Proskauer Golden Gavel Award – “Pro Bono and CSR: Special Recognition” 2024